Bionano Genomics (BNGO) Common Equity (2017 - 2026)

Bionano Genomics has disclosed Common Equity across 10 years of filings, most recently posting $37.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at $37.5 million, down 22.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.5 million (down 22.26% YoY), and the FY2025 annual result was $44.4 million, up 25.58% from the prior year.
• Common Equity came in at $37.5 million for Q1 2026 at Bionano Genomics, down from $44.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $311.2 million in Q1 2022 to a low of $35.4 million in Q4 2024.
• The 5-year median for Common Equity is $82.8 million (2024), against an average of $133.0 million.
• Across the five-year window, Common Equity tumbled 64.24% in 2024 and advanced 25.58% in 2025, its largest moves.
• Bionano Genomics' Common Equity stood at $249.4 million in 2022, then sank by 61.44% to $96.2 million in 2023, then slumped by 63.21% to $35.4 million in 2024, then rose by 25.58% to $44.4 million in 2025, then slipped by 15.67% to $37.5 million in 2026.
• The last three Common Equity figures came in at $37.5 million (Q1 2026), $44.4 million (Q4 2025), and $49.8 million (Q3 2025), per Business Quant data.